Teleflex Incorporated (NYSE:TFX) Director Benson Smith sold 8,500 shares of Teleflex stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $300.15, for a total value of $2,551,275.00. Following the transaction, the director now owns 84,913 shares of the company’s stock, valued at $25,486,636.95. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Benson Smith also recently made the following trade(s):
- On Wednesday, April 10th, Benson Smith sold 8,500 shares of Teleflex stock. The shares were sold at an average price of $305.83, for a total value of $2,599,555.00.
Shares of TFX opened at $277.05 on Friday. Teleflex Incorporated has a 12-month low of $226.02 and a 12-month high of $309.99. The company has a quick ratio of 1.39, a current ratio of 2.12 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $12.76 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 1.86 and a beta of 1.07.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. bought a new stake in shares of Teleflex in the 1st quarter valued at about $31,000. Exane Derivatives bought a new stake in shares of Teleflex during the 4th quarter valued at about $41,000. Financial Gravity Wealth Inc. bought a new stake in shares of Teleflex during the 1st quarter valued at about $52,000. Bronfman E.L. Rothschild L.P. boosted its position in shares of Teleflex by 17.7% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 239 shares of the medical technology company’s stock valued at $62,000 after purchasing an additional 36 shares in the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in shares of Teleflex by 42.2% during the 4th quarter. Valeo Financial Advisors LLC now owns 337 shares of the medical technology company’s stock valued at $87,000 after purchasing an additional 100 shares in the last quarter. 91.84% of the stock is owned by institutional investors and hedge funds.
Several analysts recently issued reports on TFX shares. Needham & Company LLC restated a “strong-buy” rating and issued a $325.00 price target (up from $300.00) on shares of Teleflex in a research note on Friday, February 22nd. Barclays set a $287.00 price target on Teleflex and gave the company a “hold” rating in a research note on Friday, February 22nd. Morgan Stanley lifted their price objective on Teleflex from $305.00 to $315.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Raymond James lifted their price objective on Teleflex from $320.00 to $348.00 and gave the company a “strong-buy” rating in a report on Wednesday, March 27th. Finally, Zacks Investment Research raised Teleflex from a “sell” rating to a “hold” rating in a report on Tuesday, February 26th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Teleflex currently has a consensus rating of “Buy” and a consensus target price of $316.13.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Article: Current Ratio
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.